Watch all of the presentation and Q&A sessions from NobleCon21 – Noble Capital Markets’ 21 annual emerging growth equity conference. Replays are available to all registered Channelchek members. Registration is free and easy.
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
Share
Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
By clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
1/23/2026
Natural Resources
MustGrow Closes $2.0 Million Non-Brokered LIFE Offering
January 23, 2026 – MustGrow Biologics Corp. (TSXV: MGRO; OTC: MGROF; FRA: 0C0) (the “Company” or “MustGrow”), is pleased to announce: the closing of its previously announced non-brokered private placement...
1/23/2026
Health
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension...
1/23/2026
Consumer
SKYX Announces Pricing of $25 Million Registered Direct Offering at $2.50 per share of Common Stock from One Fundamental Institutional Investor
MIAMI, Jan. 23, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive smart home platform technology company with over 100...
1/23/2026
Health
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced...
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.